118 related articles for article (PubMed ID: 2468106)
1. Levels of Met-enkephalin, Leu-enkephalin, substance P and cholecystokinin in the brain of the common marmoset following long term 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine treatment.
Taquet H; Nomoto M; Rose S; Jenner P; Javoy-Agid F; Mauborgne A; Benoliel JJ; Marsden CD; Legrand JC; Agid Y
Neuropeptides; 1988 Oct; 12(3):105-10. PubMed ID: 2468106
[TBL] [Abstract][Full Text] [Related]
2. Lack of change in basal ganglia neuropeptide content following subacute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment of the common marmoset.
Jenner P; Taquet H; Mauborgne A; Benoliel JT; Cesselin F; Rose S; Javoy-Agid F; Agid Y; Marsden CD
J Neurochem; 1986 Nov; 47(5):1548-51. PubMed ID: 2428937
[TBL] [Abstract][Full Text] [Related]
3. Neuropeptide levels in the basal ganglia of aged common marmosets following prolonged treatment with MPTP.
Taylor MD; de Ceballos ML; Rose S; Chong PN; Jenner P; Marsden CD
J Neural Transm Park Dis Dement Sect; 1991; 3(2):99-108. PubMed ID: 1716907
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptides and dopamine in the marmoset. Effect of treatment with 1-methyl-4-phenyl-1, 2, 3, 6 tetrahydropyridine (MPTP): an animal model for Parkinson's disease?
Allen JM; Cross AJ; Yeats JC; Ghatei MA; McGregor GP; Close SP; Pay S; Marriott AS; Tyers MB; Crow TJ
Brain; 1986 Feb; 109 ( Pt 1)():143-57. PubMed ID: 2417654
[TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity induced by prenatal exposure to MPTP on the monoaminergic and peptidergic systems of the marmoset brain.
Pérez-Otaño I; Luquin MR; Oset C; Herrero MT; Kupsch A; Oertel W; Obeso JA; Del Río J
Exp Neurol; 1995 Jan; 131(1):108-13. PubMed ID: 7534717
[TBL] [Abstract][Full Text] [Related]
6. Brain neuropeptides in progressive supranuclear palsy.
Taquet H; Javoy-Agid F; Mauborgne A; Benoliel JJ; Agid Y; Legrand JC; Hamon M; Cesselin F
Brain Res; 1987 May; 411(1):178-82. PubMed ID: 2440513
[TBL] [Abstract][Full Text] [Related]
7. Increased caudate dopamine turnover may contribute to the recovery of motor function in marmosets treated with the dopaminergic neurotoxin MPTP.
Rose S; Nomoto M; Kelly E; Kilpatrick G; Jenner P; Marsden CD
Neurosci Lett; 1989 Jul; 101(3):305-10. PubMed ID: 2505199
[TBL] [Abstract][Full Text] [Related]
8. Chronic MPTP treatment reduces substance P and met-enkephalin content in the basal ganglia of the marmoset.
Pérez-Otaño I; Herrero MT; Luquin MR; Obeso JA; Del Río J
Brain Res; 1992 Jul; 585(1-2):156-60. PubMed ID: 1380867
[TBL] [Abstract][Full Text] [Related]
9. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
Waters CM; Hunt SP; Jenner P; Marsden CD
Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
[TBL] [Abstract][Full Text] [Related]
10. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset.
Jenner P; Rupniak NM; Rose S; Kelly E; Kilpatrick G; Lees A; Marsden CD
Neurosci Lett; 1984 Sep; 50(1-3):85-90. PubMed ID: 6436758
[TBL] [Abstract][Full Text] [Related]
11. L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.
Jolkkonen J; Jenner P; Marsden CD
Brain Res Mol Brain Res; 1995 Sep; 32(2):297-307. PubMed ID: 7500841
[TBL] [Abstract][Full Text] [Related]
12. Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset.
Nomoto M; Irifune M; Fukuzaki K; Fukuda T
Neurosci Lett; 1994 Aug; 178(1):95-8. PubMed ID: 7816348
[TBL] [Abstract][Full Text] [Related]
13. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?
Russ H; Mihatsch W; Gerlach M; Riederer P; Przuntek H
Neurosci Lett; 1991 Feb; 123(1):115-8. PubMed ID: 1712088
[TBL] [Abstract][Full Text] [Related]
14. Neuropeptide metabolism on intact, regional brain slices: effect of dopaminergic agents on substance P, cholecystokinin and Met-enkephalin degradation.
Waters SM; Konkoy CS; Davis TP
J Pharmacol Exp Ther; 1995 Aug; 274(2):783-9. PubMed ID: 7543572
[TBL] [Abstract][Full Text] [Related]
15. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin.
Ueki A; Chong PN; Albanese A; Rose S; Chivers JK; Jenner P; Marsden CD
Neuropharmacology; 1989 Oct; 28(10):1089-97. PubMed ID: 2510050
[TBL] [Abstract][Full Text] [Related]
16. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset.
Pérez-Otaño I; Herrero MT; Oset C; De Ceballos ML; Luquin MR; Obeso JA; Del Río J
Brain Res; 1991 Dec; 567(1):127-32. PubMed ID: 1815820
[TBL] [Abstract][Full Text] [Related]
17. Alterations in peptide levels in Parkinson's disease and incidental Lewy body disease.
Fernandez A; de Ceballos ML; Rose S; Jenner P; Marsden CD
Brain; 1996 Jun; 119 ( Pt 3)():823-30. PubMed ID: 8673494
[TBL] [Abstract][Full Text] [Related]
18. Acute administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the adrenal glands as well as the brain in the marmoset.
Fine A; Reynolds GP; Nakajima N; Jenner P; Marsden CD
Neurosci Lett; 1985 Jul; 58(1):123-6. PubMed ID: 3931004
[TBL] [Abstract][Full Text] [Related]
19. 1-Methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine (2'-methyl-MPTP) is less neurotoxic than MPTP in the common marmoset.
Rose S; Nomoto M; Jackson EA; Gibb WR; Jenner P; Marsden CD
Eur J Pharmacol; 1990 May; 181(1-2):97-103. PubMed ID: 2117541
[TBL] [Abstract][Full Text] [Related]
20. Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets.
Rose S; Nomoto M; Jackson EA; Gibb WR; Jenner P; Marsden CD
Neuropharmacology; 1989 Nov; 28(11):1211-6. PubMed ID: 2512516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
